Use of Low-Dose Recombinant Factor Ⅶa for Uncontrolled Perioperative Bleeding
Background: Recombinant activated factor VIIa (rFVIIa) is a prohemostatic agent initially approved for use in hemophilia patients and has also been used for a diverse range of off-label indications in the context of massive uncontrolled blood loss; however, no convincing evidence exists regarding th...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2020-11-01
|
| Series: | Dose-Response |
| Online Access: | https://doi.org/10.1177/1559325820969569 |